Clinical trial
Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor
NCT00483093 · AGC Biologics S.p.A., Industry · Completed
Key facts
| NCT number | NCT00483093 |
|---|---|
| Title | Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor |
| Official title | NGR004:A Phase IB Study of NGR-hTNF in Combination With Cisplatin in Patient Affected by Advanced or Metastatic Solid Tumor |
| Lead sponsor | AGC Biologics S.p.A., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumors |
| Intervention type | Drug |
| Interventions | NGR-hTNF, Cisplatin |
| Enrollment | 22 |
| Start date | Jul 1, 2007 |
| Primary completion | Jun 1, 2010 |
| Completion | Apr 1, 2013 |
| First posted | Jun 6, 2007 |
| Last update posted | May 30, 2014 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: